

Please replace the paragraph beginning at page 33, line 5, with the following rewritten paragraph:

AF20  
--The conveyor wheel 180 then rotates the dosage forms to a nip 184 where a heated cylinder 186 that carries a microrelief transfer plate 32' on its outer surface. A microrelief pattern, preferably a high resolution diffraction relief, is electroformed or otherwise created using known techniques on the outer surface of the plate 32' and positioned to contact the layers 12 on a first face of the dosage forms 10 as they pass through the nip 184. The heat of the cylinder 186 softens the layer 12 to replicate the microrelief pattern in it. The size of the nip spacing, in conjunction with particular dosage forms, transfer plates and carrier wheel constructions (e.g., with or without a resilient backing layer under the dosage forms like layer 77 in the Figs 21-24 embodiment) produces the desired degree of pressure to affect the replication for a given layer 12 and a given degree of heating. Also, with the foregoing embodiments, a pressure in the range of 5 to 15 kg/pill, and preferably about 10 kg/pill, is preferred. A guard rail (not shown) like rail 178 may be used over the run to the nip 184, and in conjunction with other conveyor wheels runs, e.g., to hold the dosage forms on the wheel 180 after they leave the nip 184 and continue to nip 188 where the dosage forms again transfer to conveyor wheel 190.--

In the Drawings:

Fig. 25, at the lower right hand corner, "118" should be changed to --119--; and "120" should be changed to --121--. A copy of the drawing, showing the corrections marked in red, is enclosed.

In the Claims:

Please amend claim 2 as follows:

A24 2. (Amended) A pharmaceutical dosage form according to claim 1 wherein said pharmaceutical dosage form further comprises a core comprising a pharmaceutically active substance and said layer is a solid all-covering or partially-covering coating overlying said core and said information is a holographic image or effect.

Please amend claim 9 as follows:

9. (Amended) A pharmaceutical dosage form according to claim 8 wherein said outer layer completely covers said core.

A22 Please amend claim 10 as follows:

10. (Amended) A pharmaceutical dosage form according to claim 8, wherein said outer layer partially covers said core.

Please amend claim 11 as follows:

11. (Amended) A pharmaceutical dosage form according to claim 7 wherein said layer is formed from an aqueous solution of a thermoformable material selected from the group of modified cellulose, modified food starch, gelatin, waxes or vegetable gums and combinations thereof.

Please amend claim 14 as follows:

A23 14. (Amended) A pharmaceutical dosage form according to claim 8 or 9 wherein said outer layer is applied by printing or laminating.

Please amend claim 18 as follows:

A24 18. (Amended) A pharmaceutical dosage form according to claim 1 which consists essentially of said layer and, absorbed therein, a pharmaceutically active substance.

Please amend claim 19 as follows:

- A24
19. (Amended) A pharmaceutical dosage form according to claim 9 or 10 wherein said outer layer comprises at least one food grade material selected to controllably display the effects of heat and/or humidity on said microrelief.
- 

Please amend claim 21 as follows:

21. (Amended) A pharmaceutical dosage form according to claim 19 wherein said at least one food grade material retards the effects of heat on the holographic image or effect produced by said microrelief a high melting point wax.
- 

A25

Please amend claim 22 as follows:

22. (Amended) A pharmaceutical dosage form according to claim 8 or 9 wherein said solid outer layer is formed of food grade materials selected to controllably display the effects of moisture on the microrelief.

Please amend claim 23 as follows:

23. (Amended) A pharmaceutical dosage form according to claim 22 wherein said at least one food grade material that responds to display the effects of moisture on the holographic image or effect produced by said microrelief is selected from the group consisting of a highly hygroscopic sugar such as dextrose or a plasticizer such as propylene glycol.
- 

Please amend claim 26 as follows:

- A26
26. (Amended) A pharmaceutical dosage form according to claim 25 in which the modification comprises a reduction in the amount of flat areas on the core.

Please amend claim 27 as follows:

- A26
27. (Amended) A pharmaceutical dosage form according to claim 26 in which the modification comprises said core having at least one convexly curved face of not less than .6 radians.
- 

Please amend claim 34 as follows:

- A27
34. (Amended) The holographic dosage form production method of claim 30 wherein said twinning control comprises forming said core with a recess within at least one face of said core, said recess having a generally flat bottom that receives said coating layer.
- 

Please amend claim 36 as follows:

36. (Amended) The holographic dosage form production method of claim 35 wherein said recess is less than about 0.01 mm.
- 

A28

Please amend claim 37 as follows:

37. (Amended) The holographic dosage form production method of claim 29 wherein said coating includes said thermo-formable material bonding reliably with said core.

Please amend claim 38 as follows:

38. (Amended) The holographic dosage form production method of claim 29 or 37 wherein thermo-formable material is selected from the group consisting of: gelatin, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), modified food starches, waxes, vegetable gums and combinations thereof.
-

Please amend claim 45 as follows:

- Q29
45. (Amended) The holographic dosage form production method of claim 41 or 43 wherein said coated core facing said plate during said pressing is non-planar, and said belt flexibility is sufficient to allow said belt to conform to said non-planar coating desiring said pressing.

Please amend claim 48 as follows:

- A30
48. (Amended) The holographic dosage form production method of claim 47 wherein said heating raises the temperature of said diffraction pattern on said belt to a temperature in the range of 90-150°C.

Please amend claim 53 as follows:

- A31
53. (Amended) Apparatus for the continuous production of a hologram on an ingestible dosage form having a core which can contain a pharmaceutically active substance and which has been coated with a thin layer of a thermo-formable, comprising,
- a conveyor that carries the coated cores in a first direction,
  - a plate containing a holographic diffraction pattern on one surface thereof facing the coated cores on said conveyor, said plate being movable along said first direction in coordination with said carrying of said conveyor and with said one surface spaced from said coated cores,
  - a heater for rapidly raising the temperature of one of said plate and said coating to a level where said coating is formable, apparatus for pressing said one surface into said coating after said heating to replicate said diffraction pattern on said coating,
  - a cooler to rapidly lower the temperature of said coating to stabilize said diffraction pattern in said coating, and
  - apparatus to separate said one surface from said coating.